Aravas Inc. (doing business as Savara Inc.)

Aravas Inc. was a clinical-stage specialty pharmaceutical company focused on developing and commercializing product candidates for patients with rare respiratory diseases, including cystic fibrosis and pulmonary alveolar proteinosis. Its pipeline included Molgradex and AeroVanc, and it operated in the specialty-pharmaceutical segment focused on the respiratory system. Following its April 2017 business combination with Savara, Aravas became a wholly owned subsidiary.